BEATA HALASSY, PHD
Curriculum Vitae

Office Address: University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology (CEBIO); Rockefellerova 10, 10000 Zagreb, Croatia
Date of birth: 28.11.1970.
Nationality: Croat
URL for web site: https://www.oncovirlab.hr/en/team/
https://orcid.org/0000-0001-7370-0997
https://www.croris.hr/osobe/profil/4880

Beata Halassy - Academic Profile

Beata Halassy is a tenured Scientific Adviser at University of Zagreb, CEBIO. She completed her entire formal education at the Faculty of Science, University of Zagreb, earning a B.Sc. in Molecular Biology (1994), an M.Sc. (1998) and a Ph.D. in Biological Sciences (2003). She spent the first 19 years of her career in the R&D Department of Institute of Immunology Inc., a biopharmaceutical company specializing in vaccines and therapeutics derived from human and animal blood products, which strongly shaped her scientific interests. Her research focuses on the immunogenicity of complex antigens, including human and animal viruses and snake venoms, as well as on the development of passive antibody therapies for viral diseases and snakebite envenomation. Her innovations in antivenom production are protected as proprietary know-how of the former company, while her invention in virus purification for downstream processing of viral preparations is covered by granted European (EP3408383B1) and U.S. (US10597640B2) patents. During the COVID-19 pandemic, she led a national project that successfully developed and introduced serotherapy for COVID-19 in Croatia. Her current research explores the therapeutic potential of viruses in cancer treatment. Between 2024 and 2027, she is leading three complementary projects in this field, with a combined value of €1.6 million. She has authored 78 peer-reviewed publications, with 1,687 citations and an h-index of 27 (Google Scholar, May 2026).

Top 5 publications (first or corresponding author)

1. Forčić D, Mršić K, Perić-Balja M, Kurtović T, Ramić S, Silovski T, Pedišić I, Milas I, **Halassy B**. An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer. **Vaccines** 2024;12:958. IF 2024: 3.4; rang Q2
2. Ravlić S, Kurtović T, Cvetko Krajinović L, Hećimović A, Miloš M, Mateljak Lukačević S, Markotić A, **Halassy B.** What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees? **Human Vaccines and Immunotherapeutics** 2023;19(3):2270310. IF 2023: 4.1; rang Q2
3. Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, Kurolt ICh, Mačak Šafranko Ž, Mušlin T, Rnjak D, Jakšić O, Sorić E, Džepina G, Đaković Rode O, Kujavec Šljivac K, Vuk T, Jukić I, Markotić A, **Halassy B.** Is better standardization of therapeutic antibody quality in emerging diseases epidemics possible? **Frontiers in Immunology** 2022;13:816159. IF 2022: 7.3; rang Q1
4. Kurtović T, Ravlić S, Štimac A, Mateljak Lukačević S, Hećimović A, Kazazić S, **Halassy B**. Efficient and sustainable platform for preparation of a high-quality immunoglobulin G as an urgent treatment option during emerging virus outbreaks. **Frontiers in Immunology** 2022;13:889736. IF 2022: 7.3; rang Q1
5. Kurtović T, Lang Balija M, Brgles M, Sviben D, Tunjic M, Cajner H, Marchetti-Deschmann M, Allmaier G, **Halassy B**. Refinement strategy for antivenom preparation of high yield and quality. **PLOS Neglected Tropical Diseases 2019**; 13: e0007431 (23 str.). IF 2019: 3.9; rang Q1